肌肉减少症是经颈静脉肝内门体分流术后发生肝性脑病的危险因素
一项前瞻性研究纳入46例接受经颈静脉肝内门体分流术的肝硬化患者,57%存在肌肉减少症,46%在术后7±9个月发生显性肝性脑病,且发生者均为肌肉减少症患者;多因素分析显示肌肉减少症与术后肝性脑病独立相关(亚分布风险比31.3,95%CI 4.5-218.07,P<.001)。
要点
- 经颈静脉肝内门体分流术后46%患者发生显性肝性脑病,发生者均为肌肉减少症患者。
- 肌肉减少症与术后肝性脑病独立相关(亚分布风险比31.3,95%CI 4.5-218.07,P<.001)。
- 作者建议在选择经颈静脉肝内门体分流术患者时考虑肌肉减少症,术前评估营养状态。
核心结论
- 在46例肝硬化患者的前瞻性研究中,肌肉消耗(可能因氨处理减少)与经颈静脉肝内门体分流术后肝性脑病发生相关。
- 作者建议在选择经颈静脉肝内门体分流术治疗时考虑肌肉减少症。
- 作者建议经颈静脉肝内门体分流术前对肌肉减少症患者评估营养状态,可能降低肝性脑病发生率。
研究设计与样本
- 前瞻性研究,纳入2013年1月至2014年12月在意大利罗马一家三级中心连续接受经颈静脉肝内门体分流术的46例肝硬化患者。
- 患者平均年龄58.6±9.1岁,平均终末期肝病模型评分11.3±3.3,平均Child-Pugh评分7.6±1.5。
- 所有患者接受第三腰椎水平计算机断层扫描分析确定骨骼肌指数,肌肉减少症由性别特异性截断值定义。
- 估计经颈静脉肝内门体分流术后首次肝性脑病发生率时考虑死亡或肝移植的竞争风险。
主要发现
- 26例患者(57%)存在肌肉减少症。
- 21例患者(46%)在经颈静脉肝内门体分流术后7±9个月发生显性肝性脑病,根据骨骼肌指数所有这些患者均为肌肉减少症。
- 经颈静脉肝内门体分流术后无肝性脑病的25例患者中,仅5例有肌肉减少症。
- 多因素分析中,终末期肝病模型评分(亚分布风险比1.16,95%CI 1.01-1.34,P=.043)和肌肉减少症(亚分布风险比31.3,95%CI 4.5-218.07,P<.001)与经颈静脉肝内门体分流术后肝性脑病发生独立相关。
临床怎么用
- 作者认为在选择经颈静脉肝内门体分流术治疗时应考虑肌肉减少症。
- 作者建议经颈静脉肝内门体分流术前对肌肉减少症患者评估营养状态,可能降低肝性脑病发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatic encephalopathy (HE) is an important complication in patients with cirrhosis who received transjugular intrahepatic portosystemic shunts (TIPS). We investigated whether a decrease in muscle mass was associated independently with the occurrence of HE after TIPS. METHODS: We performed a prospective study of 46 consecutive patients with cirrhosis (mean age, 58.6 ± 9.1 y; mean model for end-stage liver disease score, 11.3 ± 3.3; mean Child-Pugh score, 7.6 ± 1.5) who received TIPS from January 2013 through December 2014 at a tertiary center in Rome, Italy. All patients underwent computed tomography analysis at the level of the third lumbar vertebrae to determine the skeletal muscle index; sarcopenia was defined by sex-specific cut-off values. We estimated the incidence of the first episode of HE after TIPS, taking into account the competing risk nature of the data (death or liver transplantation). RESULTS: Twenty-six patients (57%) were found to have sarcopenia. Twenty-one patients (46%) developed overt HE in the 7 ± 9 months after TIPS placement; all of these patients were sarcopenic, according to the skeletal muscle index. Of the 25 patients without HE after TIPS, only 5 had sarcopenia. In multivariate analysis, model for end-stage liver disease score (subdistribution hazard ratio, 1.16; 95% confidence interval, 1.01-1.34; P = .043) and sarcopenia (subdistribution hazard ratio, 31.3; 95% confidence interval, 4.5-218.07; P < .001) were associated independently with the development of HE after TIPS placement. CONCLUSIONS: In a prospective study of 46 patients with cirrhosis, we found muscle wasting, probably owing to reduced processing of ammonia, to be associated with the development of HE after TIPS placement. Sarcopenia should be considered in selecting patients for TIPS therapy. Nutritional status should be evaluated in patients with sarcopenia before TIPS placement, which might reduce the incidence of HE.
引用
- Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2016. PMID: 27816756. doi:10.1016/j.cgh.2016.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。